Measuring Cognitive Effects of Pediatric Oncology Treatments Using Computerized Assessments, Upcoming Webinar Hosted by Xtalks and Cogstate

Share Article

The neurocognitive effects of treatments for pediatric cancer have been acknowledged in scientific literature, yet the magnitude and long-term impact of these deficits are unclear and difficult to measure in traditional neuropsychological tests for youth with cancer. In this free webinar, learn how the advent of computerized cognitive assessments addresses these issues and brings clarity to the impacts of pediatric cancer treatment on cognition.

Xtalks Life Science Webinars

With the availability of computerized cognitive assessments, recent studies have more readily included longitudinal assessments of neurocognitive function.

In recent years the neurocognitive effects of treatments for pediatric cancers have been acknowledged in the scientific literature. However, in many cases the magnitude of these deficits and the long-term impact on cognitive maturation remain unclear. Children and adolescents present a particularly challenging population, given neurocognitive effects may impact developmental trajectories, and patients are often so unwell at the time of testing that brevity, flexibility and adaptability of the neuropsychological testing need to be considered. With the availability of computerized cognitive assessments, recent studies have more readily included longitudinal assessments of neurocognitive function.

Pharmaceutical researchers and drug developers are invited to join Adrian Schembri, PhD, Science Director at Cogstate and Kristina K. Hardy, PhD, Pediatric Neuropsychologist at the Children’s National Health System and Associate Professor at George Washington University School of Medicine for a live webinar on Monday, May 13, 2019 at 11am EDT (4pm BST/UK) where they will share their collective experience on the application of computerized cognitive assessments in pediatric oncology.

In this free webinar, attendees will learn about a computerized battery that includes measures of processing speed, attention, memory, executive function and social emotional cognition, with a pediatric specific battery available for children as young as 4 years of age. This battery has been utilized in therapeutic areas such as acute lymphoblastic leukemia (ALL), neurofibromatosis Type I, lymphoblastic lymphoma, medulloblastoma and sickle cell disease.

For more information or to register for this event, visit Measuring Cognitive Effects of Pediatric Oncology Treatments Using Computerized Assessments.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Candice Tang
Visit website